Clinical Trials Browser

Phase 2 × CIMAvax EGF × Clear all

NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Neoplasms